Crizotinib--latest champion in the cancer wars?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. 15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.Current oncology reports · 2025
   Review
2. An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.Bosnian journal of basic medical sciences · 2022
   Review
3. Inflammatory Myofibroblastic Tumor of the Hilar Bile Duct: A Case Report and Literature Review.Frontiers in surgery · 2022
   Article
4. Continuous Flow Synthesis of Anticancer Drugs.Molecules (Basel, Switzerland) · 2021
   Review
5. Inflammatory myofibroblastic tumor of the neck with thyroid invasion: a case report and literature review.Gland surgery · 2020
   Article
6. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
   Article
7. Anaplastic Lymphoma Kinase in Cutaneous Malignancies.Cancers · 2017
   Review
8. [Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015
   Article
9. Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.BioMed research international · 2015
   Review
10. The genesis of tyrosine phosphorylation.Cold Spring Harbor perspectives in biology · 2014
    Review
11. Molecular basis of drug resistance: epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors.Tuberculosis and respiratory diseases · 2013
    Review
12. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.Nature reviews. Cancer · 2013
    Review
13. Clinical and economic challenges facing pharmacogenomics.The pharmacogenomics journal · 2013
    Article
14. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.Oncogene · 2012
    Article
15. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
    Article
16. Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population.Clinics (Sao Paulo, Brazil) · 2012
    Article
17. Drug repositioning for personalized medicine.Genome medicine · 2012
    Review
18. ALK-immunoreactive neoplasms.International journal of clinical and experimental pathology · 2012
    Review
19. An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC).Cancers · 2011
    Article
20. [The EML4-ALK fusion gene in NSCLC and the clinical progress].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2011
    Review

Corrections and comments

• Comment on
  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.2010
• Comment on
  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.2010
• Comment on
  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.2010

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as